EGRX Eagle Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

EGRX [NASD]

Eagle Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	300.93	EPS (ttm)	0.16	Insider Own	12.40%	Shs Outstand	13.67M	Perf Week	-0.02%
Market Cap	669.09M	Forward P/E	16.17	EPS next Y	3.00	Insider Trans	0.00%	Shs Float	10.80M	Perf Month	0.96%
Income	2.50M	PEG	273.57	EPS next Q	0.26	Inst Own	99.20%	Short Float	17.04%	Perf Quarter	-0.14%
Sales	192.10M	P/S	3.48	EPS this Y	-51.50%	Inst Trans	0.48%	Short Ratio	10.93	Perf Half Y	-17.36%
Book/sh	13.30	P/B	3.64	EPS next Y	40.70%	ROA	0.90%	Target Price	51.67	Perf Year	-10.09%
Cash/sh	14.63	P/C	3.31	EPS next 5Y	1.10%	ROE	1.40%	52W Range	33.80 - 64.94	Perf YTD	-19.36%
Dividend	-	P/FCF	20.97	EPS past 5Y	20.20%	ROI	6.50%	52W High	-25.39%	Beta	0.98
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	59.30%	Gross Margin	71.10%	52W Low	43.34%	ATR	2.07
Employees	108	Current Ratio	1.90	Sales Q/Q	-7.60%	Oper. Margin	7.10%	RSI (14)	50.41	Volatility	4.51% 4.66%
Optionable	Yes	Debt/Eq	0.81	EPS Q/Q	-133.80%	Profit Margin	1.30%	Rel Volume	0.81	Prev Close	47.22
Shortable	Yes	LT Debt/Eq	0.17	Earnings	May 11 BMO	Payout	0.00%	Avg Volume	168.46K	Price	48.45
Recom	2.20	SMA20	3.41%	SMA50	-3.16%	SMA200	-8.89%	Volume	136,846	Change	2.60%

Nov-01-18

Downgrade

Cantor Fitzgerald

Overweight → Neutral

Oct-31-18

Downgrade

Piper Jaffray

Overweight → Neutral

Mar-21-18

Reiterated

Mizuho

Underperform

$37 → $40

Nov-09-17

Reiterated

RBC Capital Mkts

Outperform

$81 → $75

Sep-06-17

Reiterated

Mizuho

Underperform

$40 → $37

Jul-27-17

Reiterated

RBC Capital Mkts

Outperform

$94 → $81

Jul-27-17

Reiterated

Mizuho

Underperform

$57 → $40

May-09-17

Reiterated

RBC Capital Mkts

Outperform

$86 → $94

Jan-09-17

Downgrade

Mizuho

Neutral → Underperform

$78 → $64

Nov-16-16

Downgrade

Mizuho

Buy → Neutral

$78

Nov-03-16

Upgrade

Mizuho

Neutral → Buy

$62 → $78

Nov-03-16

Reiterated

RBC Capital Mkts

Outperform

$80 → $93

Oct-26-16

Reiterated

Mizuho

Buy

$65 → $62

Aug-16-16

Reiterated

Mizuho

Neutral

$47 → $65

Jun-20-16

Downgrade

Mizuho

Buy → Neutral

$66 → $47

May-10-16

Reiterated

RBC Capital Mkts

Outperform

$94 → $78

Mar-18-16

Reiterated

Mizuho

Buy

$81 → $71

Feb-26-16

Reiterated

Mizuho

Buy

$112 → $81

Dec-09-15

Initiated

Mizuho

Buy

$112

Jul-29-15

Reiterated

Piper Jaffray

Overweight

$94 → $119

Jul-09-20 12:00PM	CMS Establishes Unique J-Code for Eagle Pharmaceuticals PEMFEXY (Pemetrexed for Injection) Business Wire
Jun-27-20 09:28PM	Hedge Funds Are Buying Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
Jun-10-20 04:08PM	Edited Transcript of EGRX earnings conference call or presentation 11-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-26-20 04:30PM	Eagle Pharmaceuticals to Present at June Investor Conferences Business Wire
May-22-20 04:05PM	Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders Business Wire
May-14-20 11:50AM	Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Just Slashed This Year's Estimates Simply Wall St.
May-12-20 04:30PM	Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference Business Wire
May-11-20 12:30PM	Eagle Pharmaceuticals Inc (EGRX) Q1 2020 Earnings Call Transcript Motley Fool
08:35AM	Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates Zacks
08:14AM	Eagle Pharmaceuticals: Q1 Earnings Insights Benzinga
07:22AM	A Look At The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Simply Wall St.
06:50AM	Eagle Pharmaceuticals Reports First Quarter 2020 Results Business Wire
May-08-20 08:41AM	Why Eagle Pharmaceuticals (EGRX) Might Surprise This Earnings Season Zacks
May-07-20 06:07AM	3 Medical Product Stocks Set to Beat This Earnings Season Zacks
May-04-20 06:50AM	Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration ("FDA") Business Wire
Apr-29-20 04:30PM	Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020 Business Wire
Apr-28-20 12:33PM	Earnings Preview: Eagle Pharmaceuticals (EGRX) Q1 Earnings Expected to Decline Zacks
06:50AM	Court Issues Favorable Patent Litigation Decision for Eagle Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd. for BENDEKA (bendamustine hydrochloride injection) Business Wire
Apr-16-20 05:24PM	Covid Report: Gilead Pops On Promising Sneak Peek For Coronavirus Drug Investor's Business Daily +7.14%
06:50AM	Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro Antiviral Activity of RYANODEX® (dantrolene sodium) Against Coronavirus SARS-CoV-2 Business Wire
Apr-11-20 09:25AM	What Is Eagle Pharmaceuticals's (NASDAQ:EGRX) P/E Ratio After Its Share Price Rocketed? Simply Wall St.
Mar-30-20 06:50AM	Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation Business Wire +12.91%
Mar-24-20 02:20AM	Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT Thomson Reuters StreetEvents +5.87%
Mar-10-20 07:55AM	What Is Eagle Pharmaceuticals's (NASDAQ:EGRX) P/E Ratio After Its Share Price Tanked? Simply Wall St. +5.69%
Mar-02-20 08:15AM	Eagle Pharmaceuticals (EGRX) Surpasses Q4 Earnings and Revenue Estimates Zacks -8.80%
06:50AM	Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results Business Wire
Feb-24-20 12:30PM	Earnings Preview: Eagle Pharmaceuticals (EGRX) Q4 Earnings Expected to Decline Zacks
Feb-19-20 04:30PM	Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 Business Wire
Feb-13-20 07:50AM	Eagle Pharmaceuticals (NASDAQ:EGRX) Has A Pretty Healthy Balance Sheet Simply Wall St.
Feb-10-20 09:54AM	Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY (Pemetrexed for Injection) Business Wire
Jan-13-20 06:50AM	Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimers Disease in Collaboration With University of Pennsylvania Business Wire
Jan-09-20 08:40AM	Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study Zacks
06:50AM	Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke Business Wire
Jan-08-20 10:18AM	Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up Zacks
08:16AM	Is Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) ROE Of 15% Concerning? Simply Wall St.
Jan-07-20 09:25AM	Tyme stock rises on Eage collaboration for cancer drug MarketWatch
07:20AM	Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer Business Wire
Jan-06-20 06:50AM	Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury Business Wire
Dec-23-19 06:50AM	Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-16-19 06:50AM	Eagle Pharmaceuticals Granted Orphan Drug Designation for RYANODEX (dantrolene sodium) for Treatment of Organophosphate Exposure (Nerve Agents) Business Wire
Dec-13-19 02:53PM	Eagle Pharmaceuticals Reaches Settlement Agreement with Eli Lilly for PEMFEXY (pemetrexed for injection) Business Wire
Dec-11-19 11:25AM	Eagle Pharmaceuticals Inc (EGRX): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 06:50AM	Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate Business Wire
Dec-03-19 08:45AM	If You Had Bought Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Five Years Ago, You Could Pocket A 336% Gain Today Simply Wall St.
Nov-21-19 07:49AM	Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 06:50AM	Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 06:50AM	Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors Business Wire
Nov-12-19 08:15AM	Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates Zacks -5.61%
06:51AM	Eagle Pharmaceuticals Reports Third Quarter 2019 Results Business Wire
06:50AM	Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage Business Wire
Nov-09-19 02:26PM	Do Hedge Funds Love Eagle Pharmaceuticals Inc (EGRX)? Insider Monkey
Nov-05-19 10:31AM	Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-31-19 04:30PM	Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019 Business Wire
10:34AM	Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-28-19 08:02AM	An Intrinsic Calculation For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Suggests It's 39% Undervalued Simply Wall St.
Oct-17-19 09:28AM	New Strong Sell Stocks for October 17th Zacks
Oct-07-19 06:50AM	Eagle Pharmaceuticals Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation Business Wire
Oct-02-19 02:39PM	Here's What Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) P/E Is Telling Us Simply Wall St.
Sep-24-19 11:30AM	Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez Zacks
Sep-23-19 04:30PM	Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference Business Wire
08:32AM	5 Momentum Picks Screened on Driehaus Strategy Zacks
Sep-10-19 07:29AM	Does The Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Share Price Tend To Follow The Market? Simply Wall St.
Sep-04-19 08:40AM	Insulet (PODD) Catches Eye: Stock Jumps 8.9% Zacks
Aug-30-19 01:49PM	Edited Transcript of EGRX earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-28-19 04:30PM	Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-20-19 04:47PM	Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta Zacks
Aug-18-19 10:21AM	Should Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Be Your Next Stock Pick? Simply Wall St.
Aug-14-19 10:29AM	New Strong Buy Stocks for August 14th Zacks
Aug-09-19 06:23AM	Eagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 08:45AM	Eagle Pharmaceuticals (EGRX) Beats Q2 Earnings and Revenue Estimates Zacks
06:50AM	Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results Business Wire
Aug-05-19 06:50AM	Eagle Pharmaceuticals Announces Clinical Development Plan of Innovative Product Intended to Deliver Maximum Estrogen Receptor Inhibition in Patients with Estrogen Receptor (ER)-Positive Breast Cancer Business Wire
Aug-01-19 10:33AM	Earnings Preview: Eagle Pharmaceuticals (EGRX) Q2 Earnings Expected to Decline Zacks
Jul-29-19 04:30PM	Eagle Pharmaceuticals to Discuss Second Quarter 2019 Financial Results on August 8, 2019 Business Wire
Jul-26-19 07:54AM	Is Eagle Pharmaceuticals (NASDAQ:EGRX) Using Too Much Debt? Simply Wall St.
Jul-03-19 01:59PM	Should You Worry About Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) CEO Pay Cheque? Simply Wall St.
08:48AM	Park Service diverts $2.5 million in fees to pay for Trumps July 4th celebration \| Beto ORourke says hes unaware of his fundraising numbers MarketWatch
May-31-19 03:07PM	Here's Why I Think Eagle Pharmaceuticals (NASDAQ:EGRX) Might Deserve Your Attention Today Simply Wall St.
May-28-19 04:30PM	Eagle Pharmaceuticals, Inc. to Present at Jefferies 2019 Global Healthcare Conference Business Wire
May-15-19 06:34PM	Edited Transcript of EGRX earnings conference call or presentation 7-May-19 12:30pm GMT Thomson Reuters StreetEvents
04:30PM	Eagle Pharmaceuticals, Inc. to Present at 2019 RBC Capital Markets Global Healthcare Conference Business Wire
May-09-19 08:43PM	Hedge Funds Have Never Been More Bullish On Eagle Pharmaceuticals Inc (EGRX) Insider Monkey
May-08-19 06:00AM	Can Eagle Pharma Fly through its Oncology Trials MoneyShow
May-07-19 12:23PM	Eagle Pharmaceuticals Inc (EGRX) Q1 2019 Earnings Call Transcript Motley Fool +6.89%
08:05AM	Eagle Pharmaceuticals (EGRX) Beats Q1 Earnings and Revenue Estimates Zacks
07:04AM	Did You Miss Eagle Pharmaceuticals's (NASDAQ:EGRX) Whopping 457% Share Price Gain? Simply Wall St.
06:58AM	Eagle Pharmaceuticals: 1Q Earnings Snapshot Associated Press
06:50AM	Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results Business Wire
06:45AM	Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure Business Wire
Apr-30-19 10:32AM	Eagle Pharmaceuticals (EGRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Apr-29-19 06:50AM	Eagle Pharmaceuticals to Discuss First Quarter 2019 Financial Results on May 7, 2019 Business Wire
Apr-22-19 09:48AM	New Strong Sell Stocks for April 22nd Zacks
06:50AM	CMS Establishes Unique J-Code for BELRAPZO (Bendamustine 500mL Hydrochloride Injection) Business Wire
Apr-15-19 06:50AM	Eagle Pharmaceuticals, Inc. Expands Licensing Agreement for BENDEKA with Teva Pharmaceuticals International GmbH Business Wire
Apr-03-19 02:09PM	Don't Sell Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Before You Read This Simply Wall St.
Mar-28-19 07:35AM	Consolidated Research: 2019 Summary Expectations for Penn National Gaming, Nomad Foods, Americold Realty Trust, Cboe Global Markets, Eagle Pharmaceuticals, and National Commerce Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-07-19 12:02AM	Edited Transcript of EGRX earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 02:44PM	Eagle Pharmaceuticals Inc (EGRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:50AM	Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2018 Results Business Wire
06:30AM	Eagle Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hudson Executive Capital LP	Director	Oct 25	Sale	63.57	15,437	981,302	732,777	Oct 28 04:40 PM
Hudson Executive Capital LP	Director	Oct 24	Sale	62.53	1,494	93,412	748,214	Oct 28 04:40 PM
Hudson Executive Capital LP	Director	Oct 23	Sale	62.58	200	12,516	749,708	Oct 23 06:58 PM
Hudson Executive Capital LP	Director	Oct 22	Sale	62.68	6,567	411,618	749,908	Oct 23 06:58 PM
Hudson Executive Capital LP	Director	Oct 21	Sale	62.56	3,849	240,791	756,475	Oct 23 06:58 PM
Hudson Executive Capital LP	Director	Oct 18	Sale	62.61	1,600	100,174	760,324	Oct 18 05:29 PM
Hudson Executive Capital LP	Director	Oct 17	Sale	62.58	13,842	866,196	761,924	Oct 18 05:29 PM
Hudson Executive Capital LP	Director	Oct 16	Sale	62.50	102	6,375	775,766	Oct 18 05:29 PM
Hudson Executive Capital LP	Director	Oct 15	Sale	62.63	3,909	244,836	775,868	Oct 15 06:24 PM
Hudson Executive Capital LP	Director	Oct 11	Sale	60.39	16,300	984,419	779,777	Oct 15 06:24 PM
Hudson Executive Capital LP	Director	Oct 10	Sale	60.16	7,829	471,002	796,077	Oct 15 06:24 PM
Hudson Executive Capital LP	Director	Oct 08	Sale	60.03	1,558	93,520	803,906	Oct 09 04:13 PM
Hudson Executive Capital LP	Director	Oct 07	Sale	60.11	4,901	294,600	805,464	Oct 09 04:13 PM
Hudson Executive Capital LP	Director	Sep 17	Sale	60.00	100	6,000	810,365	Sep 19 04:13 PM
Hudson Executive Capital LP	Director	Sep 12	Sale	60.07	200	12,014	810,465	Sep 13 04:43 PM
Hudson Executive Capital LP	Director	Sep 11	Sale	60.06	1,112	66,785	810,665	Sep 13 04:43 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience